Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells.

Jung EU, Yoon JH, Lee YJ, Lee JH, Kim BH, Yu SJ, Myung SJ, Kim YJ, Lee HS.

Cancer Lett. 2010 Dec 1;298(1):9-15. doi: 10.1016/j.canlet.2010.05.020. Epub 2010 Jun 22.

PMID:
20573444
2.

Retinoic acid and its binding protein modulate apoptotic signals in hypoxic hepatocellular carcinoma cells.

Lee JH, Yoon JH, Yu SJ, Chung GE, Jung EU, Kim HY, Kim BH, Choi DH, Myung SJ, Kim YJ, Kim CY, Lee HS.

Cancer Lett. 2010 Sep 28;295(2):229-35. doi: 10.1016/j.canlet.2010.03.005. Epub 2010 Mar 28.

PMID:
20350780
3.

Enhanced interleukin-2 diphtheria toxin conjugate-induced growth suppression in retinoic acid-treated hypoxic hepatocellular carcinoma cells.

Kim BH, Yoon JH, Myung SJ, Lee JH, Lee SH, Lee SM, Lee HS.

Cancer Lett. 2009 Feb 18;274(2):259-65. doi: 10.1016/j.canlet.2008.09.025. Epub 2008 Nov 4.

PMID:
18986761
4.

N-myc downstream regulated gene 1 (NDRG1)/Cap43 enhances portal vein invasion and intrahepatic metastasis in human hepatocellular carcinoma.

Akiba J, Ogasawara S, Kawahara A, Nishida N, Sanada S, Moriya F, Kuwano M, Nakashima O, Yano H.

Oncol Rep. 2008 Dec;20(6):1329-35.

PMID:
19020710
5.

NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma.

Cheng J, Xie HY, Xu X, Wu J, Wei X, Su R, Zhang W, Lv Z, Zheng S, Zhou L.

Cancer Lett. 2011 Nov 1;310(1):35-45. doi: 10.1016/j.canlet.2011.06.001. Epub 2011 Jun 24.

PMID:
21763068
6.

Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model.

Kwak MS, Yu SJ, Yoon JH, Lee SH, Lee SM, Lee JH, Kim YJ, Lee HS, Kim CY.

J Cancer Res Clin Oncol. 2015 Nov;141(11):2037-45. doi: 10.1007/s00432-015-1990-6. Epub 2015 May 20.

PMID:
25989942
7.

Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.

Schulze-Bergkamen H, Fleischer B, Schuchmann M, Weber A, Weinmann A, Krammer PH, Galle PR.

BMC Cancer. 2006 Oct 2;6:232.

8.

Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells.

Tak E, Lee S, Lee J, Rashid MA, Kim YW, Park JH, Park WS, Shokat KM, Ha J, Kim SS.

J Hepatol. 2011 Feb;54(2):328-39. doi: 10.1016/j.jhep.2010.06.045. Epub 2010 Sep 17.

PMID:
21056497
9.

Oxygen-dependent regulation of NDRG1 in human glioblastoma cells in vitro and in vivo.

Said HM, Stein S, Hagemann C, Polat B, Staab A, Anacker J, Schoemig B, Theobald M, Flentje M, Vordermark D.

Oncol Rep. 2009 Jan;21(1):237-46.

PMID:
19082468
10.

Bid sensitizes apoptosis induced by chemotherapeutic drugs in hepatocellular carcinoma.

Miao J, Chen GG, Chun SY, Chak EC, Lai PB.

Int J Oncol. 2004 Sep;25(3):651-9.

PMID:
15289866
11.

N-Myc down-regulated gene 1 mediates proliferation, invasion, and apoptosis of hepatocellular carcinoma cells.

Yan X, Chua MS, Sun H, So S.

Cancer Lett. 2008 Apr 8;262(1):133-42. doi: 10.1016/j.canlet.2007.12.010. Epub 2008 Jan 22.

PMID:
18207320
12.

Unfolded protein response activation contributes to chemoresistance in hepatocellular carcinoma.

Al-Rawashdeh FY, Scriven P, Cameron IC, Vergani PV, Wyld L.

Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1099-105. doi: 10.1097/MEG.0b013e3283378405.

PMID:
20177386
13.

MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.

Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L, Gramantieri L.

Cancer Res. 2010 Jun 15;70(12):5184-93. doi: 10.1158/0008-5472.CAN-10-0145. Epub 2010 May 25.

14.

STAT3 & Cytochrome P450 2C9: a novel signaling pathway in liver cancer stem cells.

Myung SJ, Yoon JH, Yu SJ.

Biomed Pharmacother. 2012 Dec;66(8):612-6. doi: 10.1016/j.biopha.2012.08.011. Epub 2012 Sep 25.

PMID:
23089473
15.

Expression and biological significance of c-FLIP in human hepatocellular carcinomas.

Du X, Bao G, He X, Zhao H, Yu F, Qiao Q, Lu J, Ma Q.

J Exp Clin Cancer Res. 2009 Feb 20;28:24. doi: 10.1186/1756-9966-28-24.

16.

Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression.

Maegdefrau U, Amann T, Winklmeier A, Braig S, Schubert T, Weiss TS, Schardt K, Warnecke C, Hellerbrand C, Bosserhoff AK.

J Pathol. 2009 Aug;218(4):520-9. doi: 10.1002/path.2563.

PMID:
19431154
17.

Hypoxia increases cytoplasmic expression of NDRG1, but is insufficient for its membrane localization in human hepatocellular carcinoma.

Sibold S, Roh V, Keogh A, Studer P, Tiffon C, Angst E, Vorburger SA, Weimann R, Candinas D, Stroka D.

FEBS Lett. 2007 Mar 6;581(5):989-94. Epub 2007 Feb 7.

18.

Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells.

Pang E, Hu Y, Chan KY, Lai PB, Squire JA, Macgregor PF, Beheshti B, Albert M, Leung TW, Wong N.

Lab Invest. 2005 May;85(5):664-74.

19.

Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy.

Perugorria MJ, Castillo J, Latasa MU, Goñi S, Segura V, Sangro B, Prieto J, Avila MA, Berasain C.

Cancer Res. 2009 Feb 15;69(4):1358-67. doi: 10.1158/0008-5472.CAN-08-2545. Epub 2009 Feb 3.

20.

Biological and clinical implications of retinoic acid-responsive genes in human hepatocellular carcinoma cells.

Kanki K, Akechi Y, Ueda C, Tsuchiya H, Shimizu H, Ishijima N, Toriguchi K, Hatano E, Endo K, Hirooka Y, Shiota G.

J Hepatol. 2013 Nov;59(5):1037-44. doi: 10.1016/j.jhep.2013.06.024. Epub 2013 Jul 2.

PMID:
23831118

Supplemental Content

Support Center